Henkel AG & Co. KGaA

The UAE BioTech Symposium will be hosted in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City The UAE BioTech Symposium will attract U.S. and international BioTech owners and executives exploring opportunities in the rapidly growing BioTech sector in Abu Dhabi The inaugural symposium will be followed by quarterly events with Roadshow destinations across the Middle East ABU DHABI, UAE, Sept. 18, 2024 /PRNewswire/ -- Secondcell Bio, a U.S. BioTech company scaling-up the its platform technology invented at The Rockefeller University in the United Arab Emirates, is pleased to invite U.S. and international BioTech owners and executives to participate in the inaugural UAE BioTech Symposium, in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City, taking place on November 6-8, 2024 in Masdar City, Abu Dhabi. Further details regarding the symposium and registration information may be found at . Continue Reading Competitiveness Talks Series at IRENA at Masdar City in February, 29, 2024. Masdar City will host all quarterly editions of the UAE BioTech Symposium in partnership with AmCham Abu Dhabi's BioTech Committee. Registration is free for qualified BioTech entrepreneurs new to the UAE market. To learn more visit . Masdar City in February, 29, 2024. (PRNewsfoto/UAE BioTech Symposium,Secondcell Bio, LLC) (PRNewsfoto/UAE BioTech Symposium,Secondcell Bio, LLC) The exclusive event focusing on advancing the biotechnology sector in Abu Dhabi, UAE is expected to attract approximately 150 qualified attendees interested in exploring opportunities in the rapidly growing BioTech and Life Sciences sector in the UAE. The symposium will offer an unparalleled platform to foster collaboration, innovation, growth and catalyze progress within the sector among entrepreneurs, researchers, governmental representatives and strategic investors. The inaugural symposium will be followed by quarterly events at destinations across the Middle East. "Abu Dhabi and Dubai attract the best of the best worldwide. Our forum is for BioTech owners and company builders. Join the adventure, #comeridewithme!" says Dr. Kambiz Shekdar, Chairman of the event and recipient of the first BioTech Inventor Golden Visa via a nomination from Abu Dhabi Competitive Office (COAD) who has transitioned to Abu Dhabi with support from Abu Dhabi Investment Office (ADIO)/Abu Dhabi Residents Office (ADRO), " If even the UAE invests a tiny fraction of its wealth, we can move from Oil to Medicine." The symposium will be held at Masdar City, a pioneering sustainable urban community and world-class business and technology hub that has cultivated a thriving ecosystem of leading global organizations dedicated to evolving research and innovation: As the leading Life Sciences cluster hub in Abu Dhabi, Masdar City is proud to host a rapidly growing number of 55 companies across key clusters such as Basic Research, Pre-Clinical Research, Clinical Trials, and Logistics and Service Delivery. Pioneering organizations like the region's first Biobank, Attentive Sciences, G42, Insilico Medicine and the Emirates Drug Establishment are part of our growing ecosystem have chosen Masdar City due to its supportive ecosystem which contributes to cutting-edge advancements in the life sciences sector industry. In close collaboration with key government entities such as the Department of Health (DOH), the Abu Dhabi Investment Office (ADIO), and the Abu Dhabi Department of Economic Development (ADDED), we are fully aligned with Abu Dhabi's vision for a knowledge-based economy. Masdar City Free Zone offers the right ecosystem, with unparalleled incentives, a strategic location, and a dynamic environment that empowers businesses to excel and deliver lasting impact both locally and globally. United States Ambassador to the United Arab Emirates Martina Strong, whom Dr. Shekdar first met at AmCham Abu Dhabi's ADIPEC Kick-Off Dinner in 2023, has expressed her possible interest in making our US-UAE initiative an 'ABC' (America, Britain, Canada) initiative. UAE BioTech Symposium wishes to go one step further: We invite BioTech pioneers from around the world to come join us as the exciting new BioTech and Life Sciences sector takes root and flourishes in Abu Dhabi and throughout the region. AmCham Abu Dhabi CEO, Liz Beneski will provide opening remarks for the symposium, which is the first forum of its kind in the region. The symposium will provide attendees the opportunity to hear from distinguished international experts as well as founding members of the AmCham Abu Dhabi BioTech Committee. Key discussion topics will include growth of the BioTech sector across various regions, Emirati genomic research initiatives and the future of medicine in the UAE. Networking opportunities will be available for BioTech sector leaders to gather, discuss and explore potential areas of collaboration along with exclusive immersive visits to local laboratories and research hospitals in Abu Dhabi and Dubai for an up-close view of the cutting-edge capabilities and facilities in the UAE. "It has been a privilege working alongside Dr. Shekdar where his expertise and genuine altruistic dedication to advancing science for the benefit of all humanity have been invaluable in inspiring our team to advance our organizational objectives," says Fabienne Duchini of Secondcell Bio, "Under Dr. Shekdar's visionary leadership, the symposium will offer novel insights and a compelling vision for the future of BioTech. I hope you will join us to see all of what the UAE has to offer." Several UAE government-linked entities will have information available about their services and business incentives for companies looking to expand to the UAE, including Masdar City, Abu Dhabi Investment Office, Abu Dhabi Residents Office and [LIST-IN-FORMATION]. The symposium will offer an optional weekend program featuring a variety of cultural, leisure and lifestyle experiences in Abu Dhabi and Dubai. The weekend activities have been selected by luxury travel agency 2xceed Destination Management to enable participants to explore all that these two Emirati destinations have to offer outside the official program. We are grateful for the support of our generous corporate sponsors and exhibitors. Sponsors include Halia Therapeutics and Innova Therapeutics. International knowledge partners and corporate exhibitors include Jones Lang LaSalle Inc. (JLL), AtkinsRéalis, GRÜNECKER Patent Attorneys and Attorneys-at-Law, Sartorius Stedim Biotech GmbH, BioTech Clusters and university technology transfer offices [LIST-IN-FORMATION]. PRESS BRIEFINGS We invite members of the press to learn more. Private one-on-one briefings are available for scheduling as follows: 1) Members of UAE and GCC press: 10am to 8pm, Monday September 16, 2024, 10am to 8pm, Monday September 23, 2024 and 10am to 8pm, Monday October 7, 2024, GCC Time Zone 2) Business & technology press: 7am to 5pm, Tuesday October 8, 2024, EST Time Zone 3) All members of the press: 10am to 10pm, Wednesday October 9, 2024, GCC Time Zone To schedule a private one-on-one press briefing, please contact Fabienne Duchini at [email protected]. At a closed-door press briefing, Dr. Shekdar will share his personal experience navigating business opportunities in the UAE, adapting to the culture and his impression of the opportunities and challenges for others considering the move. We encourage members of the media including business press, U.S. and local outlets to join for a firsthand account of his experience pioneering a new sector of the knowledge based economy in the most mature market in the Arab Gulf States. Additional information for members of the press is available here: About UAE BioTech Symposium UAE BioTech Symposium in partnership with the AmCham Abu Dhabi BioTech Committee and Masdar City will host quarterly panel discussions and lab tours in Abu Dhabi, Dubai and roadshow destinations throughout the GCC and Middle East. The events are free with attendance limited to prioritize U.S. and international BioTech owners and executives. Program details will be posted online in Arabic and in English as registration for each event goes live via the AmCham Abu Dhabi website. Arabic site for scientific program: English site for scientific program: About AmCham Abu Dhabi AmCham Abu Dhabi (the trademark of the American Business Group of Abu Dhabi) is a member of the global network of American Chambers of Commerce. Active since 1986, AmCham Abu Dhabi's Mission is to promote commerce, investment, and goodwill between its membership, the United States of America and the United Arab Emirates. Our vision is to be an innovative organization creating trusted commercial partnerships that broaden U.S. - U.A.E. relationships. AmCham Abu Dhabi is an independent, not-for-profit association, comprised of Fortune 500 corporations, small and medium sized companies and prominent business leaders and entrepreneurs. For more information, visit: About Masdar City Masdar City is a pioneering sustainable urban community, a world-class business and technology hub, and a "green-print" for cities that want to be part of the solution to climate change. With one of the largest clusters of LEED Platinum buildings in the world, we are dedicated to creating a new kind of city, a new way of working and living, and a more sustainable future for everyone. The Masdar City Free Zone is a diverse, innovative, and ambitious group of over 1,000 organizations that benefit from comprehensive business support as well as the city's rich ecosystem. Tenants include the International Renewable Energy Agency (IRENA), the UAE Space Agency, Siemens Energy, G42, the Advanced Technology Research Council, several Fortune 500 companies, and the Mohamed bin Zayed University of Artificial Intelligence. The Masdar City Free Zone also includes The Catalyst, a clean-tech start-up investor powered by both Masdar City and BP. Masdar City hosts a growing residential community and has piloted two generations of autonomous vehicles. It also manages the Masdar Green REIT, a real estate investment trust dedicated to investing in sustainable real estate assets. Currently the Masdar Green REIT is worth nearly AED 2.9 billion. About AmCham Abu Dhabi BioTech Committee The AmCham BioTech Committee was formed to establish a BioTech sector in Abu Dhabi with a focus on promoting opportunities for U.S. BioTech companies with a vision to be a thought leader and facilitator for U.S. corporate interests in the emerging BioTech sector in Abu Dhabi and throughout the Middle East. Since its founding, the BioTech committee has seen a notable uptick in interest from U.S.-based companies seeking to broaden their service offerings within the region. AmCham BioTech Committee founding members include Seconcell Bio, Intelligenix Advanced Diagnostics, Extend Biosciences, Halia Therapeutics and Jones Lang LaSalle Inc (JLL). AMCHAM ABU DHABI BIOTECH COMMITTEE FOUNDING MEMBERS About Secondcell Bio Secondcell Bio™ is building public-private partnerships worldwide to scale-up the demonstrated and largely automated platform biotechnology originating from The Rockefeller University. The company was formed by Dr. Kambiz Shekdar, PhD, inventor of Chromovert® Technology. Secondcell Bio owns Chromovert® Technology. About Intelligenix Advanced Diagnostics Intelligenix Advanced Diagnostics is a biotechnology company currently developing novel diagnostic and therapeutic technology for breast and prostate cancer under the rubrics of personalized and precision medicine. Intelligenix AD is developing cutting-edge, targeted therapeutics and companion diagnostic tests that encompass five critical areas: 1) determining cancer risk, 2) cancer early detection and diagnosing, 3) determining the best course of treatment, 4) molecular-based therapeutics, and 5) monitoring treatment effectiveness. Intelligenix Advanced Diagnostic's technology aims to significantly advance cancer disease management via its impressive patented technology platform, which covers these critical areas for precision medicine and ultimately improves patient outcomes and survival rates. About Extend Biosciences Extend Biosciences Inc. is a clinical stage biotechnology company developing a novel drug delivery platform technology (D-VITylation®) that significantly improves the pharmacokinetic properties of peptides and proteins. The Company's lead D-VITylated drug candidate, EXT608, targets the rare disease Hypoparathyroidism (HPT) characterized by inappropriately low circulating levels of parathyroid hormone (PTH). EXT608 is being developed as a subcutaneously self-administered once-weekly dosing regimen for improved patient compliance and superior efficacy. Phase 2 trials in patients are underway. About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neuroinflammation, metabolic diseases, and chronic inflammation. Through a unique approach targeting inflammatory pathways, Halia aims to deliver groundbreaking treatments to improve patient outcomes in areas of high unmet medical need. About Jones Lang LaSalle Inc. (JLL) / JLL MENA / JLL Healthcare and Lifsciences For over 200 years, JLL (NYSE: JLL), a leading global commercial real estate and investment management company, has helped clients buy, build, occupy, manage and invest in a variety of commercial, industrial, hotel, residential and retail properties. A Fortune 500 company with annual revenue of $20.8 billion and operations in over 80 countries around the world, our more than 108,000 employees bring the power of a global platform combined with local expertise. Driven by our purpose to shape the future of real estate for a better world, we help our clients, people and communities SEE A BRIGHTER WAYSM. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit JLL MEA. Across the Middle East and Africa (MEA) JLL is a leading player in the real estate and hospitality services markets. The firm has worked in 35 countries across the region and employs over 1900 internationally qualified professionals across its offices in Dubai, Abu Dhabi, Riyadh, Jeddah, Al Khobar, Cairo, Casablanca, Cape Town, Johannesburg and Nairobi. JLL Healthcare and Lifesciences. JLL's Healthcare and Life Sciences consulting team offers a global network of experts with extensive regional expertise. We provide best-in-class advisory services for companies in these sectors, including feasibility studies, market entry and expansion strategies, technical and commercial due diligence. Our comprehensive consulting services help clients navigate complex challenges in the healthcare and life sciences industries. AMCHAM ABU DHABI BIOTECH COMMITTEE NEW MEMBERS About Innova Therapeutics Innova Therapeutics is a biopharmaceutical company developing a monoclonal antibody (mAb) platform targeting a novel protein that is highly expressed in both solid and hematological cancers. Innova's platform technology is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, triple negative breast cancer, multiple myeloma and pancreatic cancer. Current cancer therapies only target either the tumors directly or one component of the tumor microenvironment, while the pathway targeted with our therapy impacts both the tumor and tumor microenvironment simultaneously through a common pathway. In addition, a diagnostic is in development which has the tremendous potential for early cancer detection, as well as a prognostic marker for assessing therapeutic benefit of treatments and assessment of potential reoccurrence of cancer. UAE BioTech Symposium Cultural, Tourism and Logistics Partner About 2xceed Destination Management 2xceed delivers bespoke luxury travel, event planning, and corporate services with a focus on exceptional local expertise in UAE and all Middle East, innovative itineraries, and VIP experiences. Their offerings include tailored holidays, special event access, meetings & incentives, congress management, and comprehensive event logistics, all while adhering to principles of sustainability and corporate social responsibility. SOURCE Secondcell Bio, LLC; UAE BioTech Symposium WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Hitting macros doesn't have to be hard; introducing GHOST® PROTEIN CEREAL in "PEANUT BUTTER" and "MARSHMALLOW" CHICAGO, April 10, 2024 /PRNewswire/ -- Something cereal-ously delicious is hitting bowls near you! GHOST®, a lifestyle brand of sports nutrition products, energy drinks, dietary supplements, and apparel, is entering the food category with an epically flavored high-protein cereal line that was built in partnership with the cereal gurus over at General Mills. GHOST® PROTEIN CEREAL "PEANUT BUTTER" and GHOST® PROTEIN CEREAL "MARSHMALLOW" is the breakfast of Legends. Continue Reading GHOST® ELEVATES THE BREAKFAST GAME WITH CRAVE-WORTHY HIGH-PROTEIN CEREAL Saturday mornings (and weekday afternoons) just got a whole lot better with these crunchy protein-packed cereal puffs that fill your bowl with nostalgia without breaking macro goals. Not only does GHOST® PROTEIN CEREAL "MARSHMALLOW" include the iconic Lucky CharmsTM marshmallows, but it also has 17 grams of protein per serving. GHOST® PROTEIN CEREAL "PEANUT BUTTER" is a peanut butter lover's dream come true with 18 grams of protein and only 6 grams of sugar per serving. Both cereals are also a good source of calcium and will help keep nutrition goals on track from morning to night. Whether people want an entire bowl for breakfast or a handful as they rush out the door, GHOST® PROTEIN CEREAL will fuel the body for the gym, field, office, and beyond. (For advanced users, upgrade your bowl to a LEGEND BOWL by adding a scoop of GHOST® PROTEIN to your milk of choice.) "Functional foods are an obvious and long-awaited extension of our brand, and there couldn't be anything more authentically GHOST® than launching our own better-for-you protein cereal," said Dan Lourenco, Co-Founder and CEO of GHOST®." Cereal has been a part of the GHOST® DNA since inception. From our very first YouTube videos to the GHOST® "CEREAL MILK" protein flavors we launched, this moment has been a long time coming. Who you go to battle with is everything, and it's a privilege to work with one of the legends in the cereal game, General Mills, on this exciting product." "It's no secret that consumers are looking for more protein choices these days and the GHOST team has a reputation for disrupting the performance nutrition space with flavors that go beyond the basic chocolate or vanilla," said Nicole Ayers, Cereal Business Unit Director, General Mills. "As we look to meet consumer needs in a variety of ways across our portfolio, we're excited to combine our category-leading expertise with the strength of GHOST'S brand to bring their passionate consumers an offering in the cereal aisle." Limited quantities of GHOST® PROTEIN CEREAL are available exclusively online at GHOSTLifestyle.com on April 10 and will begin to arrive at mass retailers and grocers nationwide later this month [SRP: $9.99]. To learn more about GHOST® PROTEIN CEREAL, visit . About GHOST® GHOST® is a lifestyle brand of sports nutrition products, energy drinks, dietary supplements, and apparel. GHOST® is disrupting the sports nutrition industry by creating a lifestyle movement that includes transparent innovative products, global distribution, immersive content, key influencer partnerships, and authentic collaborations with many of the world's leading flavor brands, including OREO®, Chips Ahoy!®, Sour Patch Kids®, Sonic® Drive-In, Warheads®, Swedish Fish® and Welch's®. GHOST® also entered the food space in 2024 with its launch of high-protein cereals. GHOST® products can be found at GNC, ghostlifestyle.com, and select global retailers in over 40 countries. For more information, visit ghostlifestyle.com or connect with the brand on Instagram, X, TikTok, or Twitch. Media Contacts: Alessandra Luckey / Carissa Bass 818.478.0530 [email protected] SOURCE GHOST

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA’s continued success and growth strategies forward,” said Diem Nguyen, Chief Executive Officer. “Larry will be instrumental in helping us expand our reach on a global scale and maximize the benefits we bring to patients, customers, and shareholders.” Previously, Mr. Miller served as general counsel and secretary at Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal disorders. In this role, he provided strategic legal advice in diverse areas including securities, corporate governance, mergers and acquisitions, intellectual property, regulatory strategy, clinical development, and commercialization. He also served as general counsel and secretary at Blue Buffalo Company, advising the company through its $8 billion sale to General Mills. Earlier in his career, he held increasingly senior roles at Pfizer Inc., and was an attorney with Arnold & Porter and Weil, Gotshal & Manges. Mr. Miller earned his bachelor’s degree from Dartmouth College and law degree from Columbia Law School. “I’m excited to join the SIGA team and help support its important mission of providing solutions for unmet needs in health security and infectious diseases,” said Mr. Miller. “SIGA is well positioned for growth, and I look forward to leveraging our collective strengths to build on its momentum and enhance our contributions to global health.” ABOUT SIGA TECHNOLOGIES, INC. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. ABOUT TPOXX® TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018, and the IV formulation was approved for the same indication in 2022. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) and the Medicines and Healtcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. The EMA and UK approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com. ABOUT ORTHOPOXVIRUSES Orthopoxvirus, belonging to the family of poxvirus that infect humans, include smallpox, mpox, cowpox and vaccinia. Smallpox, a highly contagious and fatal disease, presents itself as a risk to global health security today given fears of its release accidentally or intentionally as a bioweapon. Mpox virus, similar to smallpox, causes intermittent human infections, painful lesions, and possible case fatalities. Mpox outbreaks have been observed recently in the US, Europe, and Central & West Africa. Whether through natural occurrence or potential bioweapon warfare, orthopox threatens global health. Anti-virals and vaccines serve as possible solutions to address these threats. FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA’s future business development including securing new contracts and partnerships. The words or phrases “can be,” “expects,” “may affect,” “may depend,” “believes,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that BARDA elects, in its sole discretion as permitted under the 19C BARDA Contract (the “BARDA Contract”), not to exercise all, or any, of the remaining unexercised options under those contracts, (ii) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (iii) the risk that the BARDA Contract, U.S. Department of Defense contracts are modified or canceled at the request or requirement of the U.S. Government, (iv) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally, (v) the risk that potential products, including potential alternative uses or formulations of TPOXX that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (vi) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (viii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (ix) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (x) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (xi) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xii) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xiii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiv) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xv) risks associated with actions or uncertainties surrounding the debt ceiling, (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, such as COVID-19, are ineffective and may adversely affect SIGA’s business, and (xvii) risks associated with responding to the current mpox outbreak, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred. Contacts: InvestorsMediaLaine Yonker, Edison Grouplyonker@edisongroup.comHolly Stevens, Berry & Companyhstevens@berrypr.com